Alteration of microRNA-4474/4717 expression and CREB-binding protein in human colorectal cancer tissues infected with Fusobacterium nucleatum.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2019
Historique:
received: 05 12 2018
accepted: 25 03 2019
entrez: 6 4 2019
pubmed: 6 4 2019
medline: 7 1 2020
Statut: epublish

Résumé

Colorectal cancer (CRC) is a common and highly lethal form of cancer. Although the etiologic role of Fusobacterium nucleatum (F. nucleatum) in the development of CRC has been elucidated, the specific tumor molecules involved in the progression of CRC induced by F. nucleatum have not been identified. This study investigated several miRNAs and genes involved in the progression of F. nucleatum-induced CRC by Affymetrix miRNA microarray technology and GeneChip Human Transcriptome Array 2.0. The results suggest that miR-4474 and miR-4717 are up-regulated in CRC tissues in response to F. nucleatum infection, compared with the control group (paracancerous tissues), while other genes associated with signaling pathways in cancer, including CREB-binding protein (CREBBP), STAT1, PRKACB, CAMK2B, JUN, TP53 and EWSR1, were dysregulated. Bioinformatic analysis identified CREBBP as the primary aberrantly expressed gene in F. nucleatum-induced CRC. Consistent with the microarray analysis results, real-time RT-PCR analysis demonstrated that the expression of miR-4474/4717 was upregulated while that of CREBBP mRNA was downregulated in CRC patients infected with F. nucleatum. Additionally, CREBBP was identified as a novel target of miR-4474/4717. The results of this study suggest that miR-4474 and miR-4717 are involved in the progression of F. nucleatum-induced CRC by posttranscriptionally regulating the target gene CREBBP.

Identifiants

pubmed: 30951563
doi: 10.1371/journal.pone.0215088
pii: PONE-D-18-34844
pmc: PMC6450631
doi:

Substances chimiques

MIRN4474 microRNA, human 0
MIRN4717 microRNA, human 0
MicroRNAs 0
CREB-Binding Protein EC 2.3.1.48
CREBBP protein, human EC 2.3.1.48

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0215088

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Genome Res. 2007 Oct;17(10):1537-45
pubmed: 17785539
Onco Targets Ther. 2015 Jul 08;8:1691-9
pubmed: 26185457
Physiol Genomics. 2008 Apr 22;33(2):139-47
pubmed: 18303086
Int J Oncol. 2009 Apr;34(4):1069-75
pubmed: 19287964
Nat Rev Cancer. 2008 Jan;8(1):37-49
pubmed: 18097463
World J Gastroenterol. 2017 Jul 7;23(25):4480-4490
pubmed: 28740336
Methods. 2016 Jan 15;93:84-91
pubmed: 26370280
Cancer Cell Int. 2017 Aug 7;17:75
pubmed: 28794688
Int J Mol Sci. 2018 Sep 17;19(9):
pubmed: 30227605
Nucleic Acids Res. 2004 Jan 1;32(Database issue):D277-80
pubmed: 14681412
World J Gastroenterol. 2015 Jul 21;21(27):8238-48
pubmed: 26217075
J Biol Chem. 2016 Mar 25;291(13):6714-22
pubmed: 26851278
Saudi J Gastroenterol. 2012 Jan-Feb;18(1):55-8
pubmed: 22249094
Carcinogenesis. 2012 Dec;33(12):2334-43
pubmed: 22964660
Cell. 2012 Apr 27;149(3):515-24
pubmed: 22541426
Clin Cancer Res. 2012 Jun 1;18(11):3054-70
pubmed: 22452939
Inflamm Bowel Dis. 2011 Sep;17(9):1971-8
pubmed: 21830275
Autophagy. 2012 Jul 1;8(7):1045-57
pubmed: 22647547
PLoS One. 2008 Mar 05;3(3):e1738
pubmed: 18320056
Eur J Clin Microbiol Infect Dis. 2014 Aug;33(8):1381-90
pubmed: 24599709

Auteurs

Yu-Yang Feng (YY)

Institute of Modern Biopharmaceuticals, State Key Laboratory Breeding Base of Eco-Environment and Bio-Resource of the Three Gorges Area, Key Laboratory of Eco-environments in Three Gorges Reservoir Region, Ministry of Education, School of Life Sciences, Southwest University, Chongqing, China.
Department of Clinical Microbiology and Immunology, Southwest Hospital & College of Pharmacy and Medical Laboratory Science, Army Medical University (Third Military Medical University), Chongqing, China.

Dong-Zhu Zeng (DZ)

Digestive Disease Center, Third Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Ya-Nan Tong (YN)

Department of Clinical Microbiology and Immunology, Southwest Hospital & College of Pharmacy and Medical Laboratory Science, Army Medical University (Third Military Medical University), Chongqing, China.

Xiao-Xue Lu (XX)

Department of Clinical Microbiology and Immunology, Southwest Hospital & College of Pharmacy and Medical Laboratory Science, Army Medical University (Third Military Medical University), Chongqing, China.

Guo-Dong Dun (GD)

Department of Clinical Microbiology and Immunology, Southwest Hospital & College of Pharmacy and Medical Laboratory Science, Army Medical University (Third Military Medical University), Chongqing, China.

Bin Tang (B)

Department of Clinical Microbiology and Immunology, Southwest Hospital & College of Pharmacy and Medical Laboratory Science, Army Medical University (Third Military Medical University), Chongqing, China.

Zhu-Jun Zhang (ZJ)

Department of Hospital Infection Control, Southwest Hospital, Army Medical University (Third Military Medical University), Chongqing, China.

Xin-Li Ye (XL)

Digestive Disease Center, Third Affiliated Hospital of Chongqing Medical University, Chongqing, China.

Qian Li (Q)

Department of Clinical Microbiology and Immunology, Southwest Hospital & College of Pharmacy and Medical Laboratory Science, Army Medical University (Third Military Medical University), Chongqing, China.

Jian-Ping Xie (JP)

Institute of Modern Biopharmaceuticals, State Key Laboratory Breeding Base of Eco-Environment and Bio-Resource of the Three Gorges Area, Key Laboratory of Eco-environments in Three Gorges Reservoir Region, Ministry of Education, School of Life Sciences, Southwest University, Chongqing, China.

Xu-Hu Mao (XH)

Department of Clinical Microbiology and Immunology, Southwest Hospital & College of Pharmacy and Medical Laboratory Science, Army Medical University (Third Military Medical University), Chongqing, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH